TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25870329

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13) - 3 doses at 1-month intervals, 1 additional dose 6 months later, followed by 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) 1 month later
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: 4-dose regimen of PCV13 followed by PPSV23
Number of subjects: 251
Study: 25871496

Group type: EXPERIMENTAL
Intervention: Youths with ADHD
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Youths with ADHD treated with methylphenidate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study: 25872574

Group type: EXPERIMENTAL
Intervention: Coloplast Titan IPP with NLMT and postoperative rehabilitation (daily inflation for 1 year)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitation (daily inflation for 1 year)
Number of subjects: 40
Study: 25872754

Group type: EXPERIMENTAL
Intervention: Mobile phone-delivered physical activity intervention during a 3-week run-in period using a mobile phone app and wearing a pedometer.
Number of subjects: 318

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 318
Study: 25872787

Group type: EXPERIMENTAL
Intervention: Tafamidis 20 mg daily
Number of subjects: 31
Study: 25872904

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) analysis
Number of subjects: 450

Group type: COMPARATOR
Intervention: Exercise Stress Testing (EST)
Number of subjects: 450
Study: 25873979

Group type: EXPERIMENTAL
Intervention: Yogic Breathing (YB) - two exercises for ten minutes each, total of twenty minutes in a single session.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Attention Controls (AC) - reading a text of choice for 20 minutes.
Number of subjects: 20
Study: 25874001

Group type: EXPERIMENTAL
Intervention: AZD0530 50 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AZD0530 100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AZD0530 125 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25874991

Group type: EXPERIMENTAL
Intervention: TwHF extract (10 mg three times daily for 12 months)
Number of subjects: 18
Study: 25876471

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5mg
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25mg
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1272
Study: 25876473

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5mg
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25mg
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Interferon β-1a intramuscular 30μg
Number of subjects: 1292
Study: 25876560

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study: 25877437

Group type: EXPERIMENTAL
Intervention: Health risk factors assessment (obesity, depressive symptoms, smoking)
Number of subjects: 630
Study: 25877635

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-α) 6 MIU
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-α)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Interferon-beta (IFN-β)
Number of subjects: 10
Study: 25877962

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine for 3 days + primaquine
Number of subjects: 107

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine for 3 days + no primaquine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Triple mutant (Cys580Tyr)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Non-triple mutant
Number of subjects: 107
Study: 25878323

Group type: EXPERIMENTAL
Intervention: Atrioventricular-nodal stimulation (AVNS)
Number of subjects: 44
Study: 25878729

Group type: EXPERIMENTAL
Intervention: Obesity group (CTRP3 levels)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Hypertensive subjects (CTRP3 levels)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Correlation with waist circumference (WC)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Correlation with waist-to-hip ratio (WHR)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Correlation with homeostasis model assessment of IR (HOMA-IR)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Correlation with triglycerides (TG)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Correlation with fasting blood glucose (FBG)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Correlation with fasting insulin (FINS)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Correlation with homeostasis model assessment of β-cell insulin secretion (HOMA-β)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Multiple stepwise regression analysis
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: CTRP3 as an independent factor
Number of subjects: 246
Study: 25879416

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system (≤8 mg/24 h) as add-on to oral DA
Number of subjects: 90
Study: 25879713

Group type: EXPERIMENTAL
Intervention: Early response (≤72 hours) with Definition 1 (resolution of fever within 72 hours)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Early response (≤72 hours) with Definition 2
Number of subjects: 600

Group type: COMPARATOR
Intervention: No early response (Definition 1)
Number of subjects: 600

Group type: COMPARATOR
Intervention: No early response (Definition 2)
Number of subjects: 600
Study: 25879747

Group type: EXPERIMENTAL
Intervention: Interim PET/CT using the Deauville five-point scale (5-PS)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Interim PET/CT using ΔSUVmax
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Interim PET/CT using ΔMTV2.5
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combined approach using visual, SUV-based, and MTV-based assessment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Favorable group based on combined assessment
Number of subjects: 63
Study: 25879807

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretics (particularly antialdosteronic diuretic agents)
Number of subjects: 0
Study: 25879867

Group type: COMPARATOR
Intervention: One dose of MVA
Number of subjects: 745

Group type: COMPARATOR
Intervention: Two doses of MVA
Number of subjects: 745

Group type: COMPARATOR
Intervention: Two doses of placebo
Number of subjects: 745

Group type: COMPARATOR
Intervention: Single dose of MVA (for vaccinia-experienced subjects)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Overall vaccination with MVA
Number of subjects: 745
Study: 25880400

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily for 12 weeks (with optional increase to 120 mg after 8 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily for 12 weeks
Number of subjects: 32
Study: 25880823

Group type: EXPERIMENTAL
Intervention: Universal HIV Test and Treat (UTT) strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TasP intervention package
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UTT implementation
Number of subjects: 0
Study: 25881074

Group type: EXPERIMENTAL
Intervention: 24-hour waist-worn accelerometer protocol in U.S. ISCOLE children
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: Waking wear time for U.S. ISCOLE children
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Waking wear time for NHANES children
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Comparison of waking wear time
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: 24-hour waist-worn accelerometry protocol
Number of subjects: 1077

Group type: COMPARATOR
Intervention: 24-hour protocol vs waking wear time protocol
Number of subjects: 1077
Study: 25881192

Group type: EXPERIMENTAL
Intervention: Internet recruitment strategy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Diabetes clinics
Number of subjects: 45

Group type: COMPARATOR
Intervention: Disease register
Number of subjects: 45
Study: 25881582

Group type: EXPERIMENTAL
Intervention: Taxometric analysis using MAXCOV/MAMBAC
Number of subjects: 3721

Group type: EXPERIMENTAL
Intervention: Information-theoretic latent distribution modeling (ITLDM)
Number of subjects: 3721

Group type: EXPERIMENTAL
Intervention: Structural equation mixture modeling (SEMM)
Number of subjects: 3721
Study: 25881847

Group type: EXPERIMENTAL
Intervention: Busulfan and fludarabine (Flu-BU) conditioning regimen after FLAG-IDA chemotherapy
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Busulfan and fludarabine (Flu-BU) conditioning regimen
Number of subjects: 16
Study: 25881930

Group type: EXPERIMENTAL
Intervention: Leadless cardiac pacemaker (LCP)
Number of subjects: 31
Study: 25882172

Group type: EXPERIMENTAL
Intervention: dTpa-IPV booster dose
Number of subjects: 211

Group type: COMPARATOR
Intervention: dTpa-IPV
Number of subjects: 211

Group type: COMPARATOR
Intervention: dTpa+IPV
Number of subjects: 211

Group type: COMPARATOR
Intervention: Td-IPV
Number of subjects: 211
Study: 25882205

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25882434

Group type: EXPERIMENTAL
Intervention: Renal angina index (RAI) and biomarkers (NGAL, KIM-1, l-FABP, IL-18)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Renal angina index (RAI)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Incorporation of biomarkers with RAI
Number of subjects: 5000
Study: 25882487

Group type: EXPERIMENTAL
Intervention: Subclinical atherosclerosis presence
Number of subjects: 4184

Group type: EXPERIMENTAL
Intervention: Intermediate and generalized atherosclerosis
Number of subjects: 4184

Group type: EXPERIMENTAL
Intervention: Plaque presence
Number of subjects: 4184

Group type: EXPERIMENTAL
Intervention: Coronary artery calcification
Number of subjects: 4184

Group type: EXPERIMENTAL
Intervention: Subclinical disease in low FHS risk
Number of subjects: 4184

Group type: EXPERIMENTAL
Intervention: Subclinical disease in high FHS risk
Number of subjects: 4184
Study: 25882607

Group type: EXPERIMENTAL
Intervention: NAVA levels from 0 to 3.0 cmH₂O/μV, applied in steps of 0.3 cm H₂O/μV every 3 minutes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Matching EAdipk between non-assisted and assisted breaths
Number of subjects: 12
Study: 25883641

Group type: EXPERIMENTAL
Intervention: Marine protein supplement (MPS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25883789

Group type: EXPERIMENTAL
Intervention: Oral salt and water
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous isotonic saline
Number of subjects: 50
Study: 25884189

Group type: EXPERIMENTAL
Intervention: H1 DNA vaccine (4 mg intramuscularly with Biojector, 3 doses at 4-week intervals)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: MIV boost (licensed H1N1 MIV)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: H1 DNA vaccine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: MIV boost
Number of subjects: 38
Study: 25884256

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 218

Group type: COMPARATOR
Intervention: Microsurgery
Number of subjects: 218
Study: 25884259

Group type: EXPERIMENTAL
Intervention: Giant intracranial aneurysms (GIAs) with perianeurysmal edema (PAE)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Giant intracranial aneurysms (GIAs) of the middle cerebral artery (MCA)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Giant intracranial aneurysms (GIAs) of the cavernous internal carotid artery (ICA)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Giant intracranial aneurysms (GIAs) with PAE
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Giant intracranial aneurysms (GIAs)
Number of subjects: 69
Study: 25884460

Group type: EXPERIMENTAL
Intervention: Bemiparin (3500 IU/day)
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Enoxaparin (4000 IU/day)
Number of subjects: 7020

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Bemiparin
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 7020
Study: 25884515

Group type: EXPERIMENTAL
Intervention: vemurafenib 960 mg administrated p.o. twice daily for 28-day treatment cycles
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: vemurafenib 960 mg administrated p.o. twice daily
Number of subjects: 11
Study: 25884546

Group type: EXPERIMENTAL
Intervention: Ischemic stroke patients' knowledge about family history (FH) of cardiovascular disease (CVD)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Knowledge about FH of stroke
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Knowledge about FH of stroke in grandmothers
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Comparison of FH reporting by sex
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Knowledge about CAD compared to stroke
Number of subjects: 257
Study: 25884954

Group type: EXPERIMENTAL
Intervention: Combined-Apgar
Number of subjects: 1855

Group type: COMPARATOR
Intervention: Specified-Apgar
Number of subjects: 1855

Group type: COMPARATOR
Intervention: Expanded-Apgar
Number of subjects: 1855
Study: 25885260

Group type: COMPARATOR
Intervention: KCC (King's College Criteria)
Number of subjects: 803

Group type: COMPARATOR
Intervention: KCC-CART (KCC Classification and Regression Tree)
Number of subjects: 803

Group type: COMPARATOR
Intervention: NEW-CART (using MELD, lactate, mechanical ventilation)
Number of subjects: 803
Study: 25885289

Group type: EXPERIMENTAL
Intervention: TG/HDL-C ratio >3.29
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: TG/HDL-C ratio
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Plasma ADMA levels
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: History of diabetes mellitus
Number of subjects: 197
Study: 25885436

Group type: EXPERIMENTAL
Intervention: Dobutamine cardiovascular magnetic resonance (DCMR) stress testing
Number of subjects: 278
Study: 25885482

Group type: EXPERIMENTAL
Intervention: PIN3 survey
Number of subjects: 42
Study: 25885553

Group type: EXPERIMENTAL
Intervention: 5% Imiquimod (IMQ) cream, applied once a day, 5 days per week, for 8-16 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5% Imiquimod (IMQ) cream for lesions >10 mm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5% Imiquimod (IMQ) cream for lesions <10 mm
Number of subjects: 24
Study: 25885665

Group type: EXPERIMENTAL
Intervention: Total leukocyte count
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Neutrophil count
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Monocyte count
Number of subjects: 500
Study: 25885799

Group type: EXPERIMENTAL
Intervention: Moderate altitude (1,900 m) hiking vacation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low altitude (300 m) hiking vacation
Number of subjects: 14
Study: 25886014

Group type: EXPERIMENTAL
Intervention: Telemedicine training and counselling via video conference
Number of subjects: 50
Study: 25886021

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) dispersible formulation, 20 mg artemether/120 mg lumefantrine, given twice-daily for three days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic data for artemether and dihydroartemisinin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Three-day regimen of AL dispersible formulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dosing recommendations for infants <5 kg
Number of subjects: 20
Study: 25886058

Group type: EXPERIMENTAL
Intervention: IRE ablation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MRI imaging
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CEUS imaging
Number of subjects: 10
Study: 25886275

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BVZ) with capecitabine and radiotherapy
Number of subjects: 41
Study: 25886363

Group type: EXPERIMENTAL
Intervention: PROP observational prospective cohort study
Number of subjects: 750
Study: 25886388

Group type: EXPERIMENTAL
Intervention: Intimate Terrorism (IT)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Situational Couple Violence (SCV)
Number of subjects: 613
Study: 25886410

Group type: EXPERIMENTAL
Intervention: CLART HPV2 genotyping assay
Number of subjects: 401

Group type: COMPARATOR
Intervention: Linear Array (LA)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Hybrid Capture 2 (HC2)
Number of subjects: 401
Study: 25886603

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.03 ml)
Number of subjects: 4
Study: 25886605

Group type: EXPERIMENTAL
Intervention: Panagen (5 mg, 6 tablets daily for 18 days during chemotherapy)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (6 tablets daily for 18 days during chemotherapy)
Number of subjects: 80
Study: 25886678

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 16 weeks
Number of subjects: 0
Study: 25886727

Group type: EXPERIMENTAL
Intervention: MicroRNAs as potential biomarkers and therapeutic targets after cardiac arrest
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current predictive methods and biomarkers
Number of subjects: 0
Study: 25886752

Group type: EXPERIMENTAL
Intervention: Mindfulness Training for Smokers via web-based video instruction with phone support
Number of subjects: 26
Study: 25886793

Group type: EXPERIMENTAL
Intervention: NIV-NAVA (60 minutes)
Number of subjects: 13
Study: 25886845

Group type: EXPERIMENTAL
Intervention: Difficult Colonoscopy Score (DCS) > 1
Number of subjects: 616

Group type: COMPARATOR
Intervention: Difficult Colonoscopy Score (DCS) ≤ 1
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Difficult Colonoscopy Score (DCS)
Number of subjects: 616
Study: 25886928

Group type: EXPERIMENTAL
Intervention: stavudine + didanosine
Number of subjects: 1594

Group type: EXPERIMENTAL
Intervention: zidovudine (cumulative exposure ≥ 1 year)
Number of subjects: 1594

Group type: EXPERIMENTAL
Intervention: tenofovir (cumulative exposure ≥ 1 year)
Number of subjects: 1594

Group type: EXPERIMENTAL
Intervention: emtricitabine (cumulative exposure ≥ 1 year)
Number of subjects: 1594
Study: 25887027

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure titration from 65 mmHg to normal levels
Number of subjects: 19
Study: 25887045

Group type: EXPERIMENTAL
Intervention: Preference-adaptive randomization
Number of subjects: 0
Study: 25887094

Group type: EXPERIMENTAL
Intervention: Cleanroom sleeping environment for two weeks
Number of subjects: 10
Study: 25887097

Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 58

Group type: COMPARATOR
Intervention: Patients with smoking status
Number of subjects: 58

Group type: COMPARATOR
Intervention: Patients with smoking cessation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Patients with cystic lesions
Number of subjects: 58
Study: 25887336

Group type: EXPERIMENTAL
Intervention: Single oral 150 mg dose of fluconazole
Number of subjects: 157
Study: 25887461

Group type: EXPERIMENTAL
Intervention: ReDO™ program
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Therapists' rating
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Clients' perceptions
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: ReDO™ group
Number of subjects: 84

Group type: COMPARATOR
Intervention: CAU group
Number of subjects: 84
Study: 25887576

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard care sedation (propofol or midazolam)
Number of subjects: 2
Study: 25887603

Group type: EXPERIMENTAL
Intervention: Conventional methods combined with PCR
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: PCR
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: OP swab for S. pneumoniae qPCR
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Serology
Number of subjects: 267
Study: 25887777

Group type: EXPERIMENTAL
Intervention: AFM13 at doses of 0.01 to 7 mg/kg body weight
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AFM13 at doses of ≥1.5 mg/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AFM13 treatment
Number of subjects: 28
Study: 25888272

Group type: EXPERIMENTAL
Intervention: ramucirumab 8 mg/kg on days 1 and 15 and paclitaxel 80 mg/m² on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 6
Study: 25888299

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 25
Study: 25888397

Group type: EXPERIMENTAL
Intervention: Renal tubular acidosis (RTA) in patients with hyperchloremic acidosis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hyperchloremic acidosis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Other acid-base disturbances
Number of subjects: 100
Study: 25888403

Group type: EXPERIMENTAL
Intervention: Closed-loop fluid administration system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual management (Control)
Number of subjects: 40
Study: 25888646

Group type: EXPERIMENTAL
Intervention: PCV13 (3 doses) followed by PPSV23 (1 dose)
Number of subjects: 301
Study: 25888856

Group type: EXPERIMENTAL
Intervention: Couples' Health CoOp intervention targeting men who use alcohol and other drugs and engage in unprotected sex, and their main female sex partners. The intervention includes components addressing substance use, sex risk, HIV and other STIs, gender roles, gender-based violence, communication skills, and goal-setting activities.
Number of subjects: 0
Study: 25888961

Group type: COMPARATOR
Intervention: Entropy in the central retinal artery (CRA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Entropy in the ophthalmic artery
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Resistive index in the CRA
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pulsatility index in the CRA
Number of subjects: 42
Study: 25889044

Group type: EXPERIMENTAL
Intervention: Pradigastat 20 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pradigastat 40 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pradigastat
Number of subjects: 6
Study: 25889305

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (3 g/day for 6 weeks)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation
Number of subjects: 208
Study: 25889498

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 610660

Group type: COMPARATOR
Intervention: Non-DPP-4 inhibitor OAD
Number of subjects: 610660